# Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

> **NCT02408432** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Cardiomyopathy
- Heart Failure

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Standard of Care
- **DRUG:** Mesenchymal Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT02408432
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-11
- **Primary completion:** 2021-12-08
- **Final completion:** 2021-12-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02408432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02408432, "Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02408432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*